Eisai Seeks To End Aricept Deal With Pfizer Once Wyeth Acquired
This article was originally published in PharmAsia News
Executive SummaryEisai is considering an end to its co-promotion deal with U.S.-based Pfizer for the Japanese drug maker's Aricept (donepezil) for treating Alzheimer's Disease. Eisai has not disclosed its plans, but Pfizer said in a regulatory filing it intended to fight Eisai's plan to take back the drug once Pfizer's purchase of fellow U.S. drug maker Wyeth is completed. Pfizer said Eisai has no legal basis for ending the partnership for co-promoting the $482 million-a-year drug. In the filing, Pfizer said Eisai indicated it had the right to end the contract. (Click here for more - a subscription may be required
You may also be interested in...
Cannabidiol (CBD) represents an intriguing opportunity for cosmetics, without the statutory obstacles faced by food and dietary supplement companies. Cosmetics marketers are taking advantage, but the FDA’s recent warning letter blitz is a reminder that CBD-infused beauty products are bound by the same rules that apply to other cosmetics.
Analyzing Quality Data Is Essential. Here’s What One Expert Says Your Firm Should Do To Stay In FDA’s Good Graces
Device makers should make sure they have adequate resources to analyze quality data they take in so they can prevent the recurrence of nonconforming products, processes and procedures. That’s just one nugget of advice from former FDA investigations branch director Ricki Chase, who explains why collecting and properly handling such data is critical to complying with agency expectations in this Medtech Insight Q&A interview.